9-(4-bromobutyl)-2-butoxy-8-methoxy-9H-purine-6-amine | 866268-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(4-bromobutyl)-2-butoxy-8-methoxy-9H-purine-6-amine
• 英文别名: 9-(4-bromobutyl)-2-butoxy-8-methoxy-9H-purin-6-amine；9-(4-bromobutyl)-2-butoxy-8-methoxyadenine；9-(4-bromobutyl)-2-butoxy-8-methoxypurin-6-amine
• CAS: 866268-46-4
• 化学式: C₁₄H₂₂BrN₅O₂
• 分子量: 372.265
• InChiKey: GWUSLIGFZUMZHR-UHFFFAOYSA-N

物化性质

• 沸点：
  533.2±60.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  88.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  9-(4-bromobutyl)-2-butoxy-8-methoxy-9H-purine-6-amine 在 甲胺 作用下， 以 水 、 乙腈 为溶剂， 反应 1.5h， 生成 6-amino-2-butoxy-9-[4-(methylamino)butyl]-7H-purin-8-one
  参考文献：
  名称：

  9-SUBSTITUTED 8-OXOADENINE COMPOUND

  摘要：

  公开号：

  EP1728793B1
• 作为产物：
  描述：

  1,4-二溴丁烷 、 2-butoxy-8-methoxy-9H-purine-6-amine trifluoroacetic acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以70%的产率得到9-(4-bromobutyl)-2-butoxy-8-methoxy-9H-purine-6-amine
  参考文献：
  名称：

  9-SUBSTITUTED 8-OXOADENINE COMPOUND

  摘要：

  公开号：

  EP1728793B1

文献信息

• METHOD FOR PREPARING ADENINE COMPOUND
  申请人：Kurimoto Ayumu

  公开号：US20110054168A1

  公开（公告）日：2011-03-03

  A method for preparing compound (4): wherein m and n are independently an integer of 2 to 5, R 1 is C 1-6 alkyl group, R 2 and R 3 are combined with an adjacent nitrogen atom to form pyrrolidine, morpholine, thiomorpholine, etc., and R 4 is C 1-3 alkyl group, or a pharmaceutically acceptable salt, which is useful as a medicament, which comprises step (a) for preparing compound (2): wherein m, n, R 1 , R 2 and R 3 are the same as defined above, or its salt which comprises subjecting compound (1): wherein k is an integer of 1 or 2, R is hydrogen atom, halogen atom, etc., or a salt thereof to debenzylation reaction, and then step (b) for preparing compound (4) or a pharmaceutically acceptable salt which comprises reacting compound (2) or its salt prepared in the above step (a) or salt thereof and compound (3): wherein R 4 is C 1-3 alkyl group, in the presence of a boron-containing reducing agent.

  制备化合物（4）的方法：其中m和n分别是2到5的整数，R1是C1-6烷基，R2和R3与相邻的氮原子结合形成吡咯烷，吗啉，硫代吗啉等，R4是C1-3烷基，或者是药学上可接受的盐，可用作药物，包括以下步骤：制备化合物（2）的步骤：其中m，n，R1，R2和R3与上述定义相同，或其盐，包括将化合物（1）：其中k是1或2的整数，R是氢原子，卤原子等，或其盐，经过脱苄基化反应，然后制备化合物（4）或药学上可接受的盐的步骤，包括在含硼还原剂的存在下，将在上述步骤（a）中制备的化合物（2）或其盐或其盐和化合物（3）：其中R4是C1-3烷基，在反应。
• Novel Adenine Compound
  申请人：Hashimoto Kazuki

  公开号：US20080269240A1

  公开（公告）日：2008-10-30

  An adenine compound useful as a medicine represented by the following formula (1): [wherein R 1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A 1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A 2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L 1 and L 2 are independently, substituted straight or branched alkylene or a single bond, etc.; L 3 is optionally substituted straight or branched alkylene, etc.; R 2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.

  以下式子（1）所表示的一种腺嘌呤化合物，可用作药物：[其中，R1是卤素原子、可选取代烷基、可选取代芳基等；X是氧原子、硫原子、单键等；A1是可选取代和可饱和的4至8元杂环基，包含1至2个从1至3个氮原子、0至1个氧原子和0至1个硫原子中选取的杂原子；A2是可选取代的6至10环芳烃基或可选取代的5至10元杂环芳烃基；L1和L2是独立的、取代的直链或支链烷基或单键等；L3是可选取代的直链或支链烷基等；R2是氢原子、可选取代烷基等。]或其药学上可接受的盐。
• PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS
  申请人：Abbot Philip

  公开号：US20090082332A1

  公开（公告）日：2009-03-26

  The present invention provides compounds of formula (I) wherein R 1 , Y 1 , X 1 , Z 1 , X 2 , Y 2 , A, Y 3 , n, R and R 2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）化合物，其中R1、Y1、X1、Z1、X2、Y2、A、Y3、n、R和R2如规范中所定义，以及它们的制备方法、含有它们的药物组合物和它们在治疗中的应用。
• 9-Substituted 8-oxoadenine compound
  申请人：Kurimoto Ayumu

  公开号：US20070190071A1

  公开（公告）日：2007-08-16

  The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z 1 represents alkylene, X 2 represents oxygen atom, sulfur atom, SO 2 , NR 5 , CO, CONR 5 , NR 5 CO and the like, Y 1 , Y 2 and Y 3 represent independently a single bond or an alkylene group, X 1 represents oxygen atom, sulfur atom, NR 4 (R 4 is hydrogen atom or an alkyl group) or a single bond, R 2 represents a substituted or unsubstituted alkyl group, R 1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

  本发明提供了一种具有免疫调节活性的8-氧腺嘌呤化合物，例如干扰素诱导活性，并且可用作抗病毒剂和抗过敏剂，其化学式如下（1）所示：[其中，环A代表6-10个成员的芳香环烷基环等，R代表卤素原子，烷基等，n代表0-2的整数，Z1代表烷基，X2代表氧原子，硫原子，SO2，NR5，CO，CONR5，NR5CO等，Y1，Y2和Y3独立地代表单键或烷基，X1代表氧原子，硫原子，NR4（R4为氢原子或烷基）或单键，R2代表取代或未取代的烷基，R1代表氢原子，羟基，烷氧基，烷氧羰基或卤代烷基]或其药学上可接受的盐。
• NOVEL ADENINE COMPOUND
  申请人：Millichip Ian

  公开号：US20090099216A1

  公开（公告）日：2009-04-16

  A novel adenine compound represented by the formula (1): wherein Z represents (un)substituted alkylene, a single bond, etc.; R 1 represents an (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl group; R 2 represents hydrogen or (un)substituted alkyl; R 3 , R 4 and R 5 each independently represents an (un)substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl group, provided that R 3 and R 5 may be bonded to each other to form a 3- to 7-membered, saturated carbocycle or heterocycle in cooperation with the adjacent carbon atom; and X represents oxygen, sulfur, SO 2 , NR 6 (R 6 represents hydrogen or alkyl), or a single bond, or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.

  一种新型腺嘌呤化合物，由公式（1）表示：其中Z代表（未）取代的烷基，单键等；R1代表（未）取代的烷基，烯基，炔基，环烷基，芳基或杂环芳基；R2代表氢或（未）取代的烷基；R3、R4和R5各自独立地表示（未）取代的烷基，烯基，炔基，芳基或杂环芳基，但R3和R5可以与相邻的碳原子合作形成3-至7-环的饱和碳环或杂环；X代表氧，硫，SO2，NR6（R6代表氢或烷基）或单键，或化合物的药学上可接受的盐。该化合物和盐可用作药物。